Inbrija

Parkinson Disease, advanced Motor fluctuations, Carbon Monoxide Poisoning + 5 more
Treatment
10 FDA approvals
20 Active Studies for Inbrija

What is Inbrija

LevodopaThe Generic name of this drug
Treatment SummaryLevodopa is a medication used to treat Parkinson's Disease. It works by crossing the blood-brain barrier and converting into dopamine, a neurotransmitter responsible for movement. To prevent levodopa from being broken down too quickly, it is usually taken with a drug called carbidopa. The FDA approved the combination of levodopa and carbidopa as Sinemet in 1975.
Sinemetis the brand name
image of different drug pills on a surface
Inbrija Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Sinemet
Levodopa
1975
272

Approved as Treatment by the FDA

Levodopa, also called Sinemet, is approved by the FDA for 10 uses including Parkinson Disease and Paralysis agitans .
Parkinson Disease
Used to treat Parkinsonism in combination with Carbidopa
Paralysis agitans
Used to treat Paralysis agitans in combination with Carbidopa
carbon monoxide intoxication
Used to treat carbon monoxide intoxication in combination with Carbidopa
Parkinson Disease
Used to treat Paralysis agitans in combination with Carbidopa
Parkinson's Disease (PD)
Used to treat Parkinson's Disease (PD) in combination with Carbidopa
Parkinsonism
Used to treat Parkinsonism in combination with Carbidopa
Parkinson's Disease
Used to treat Parkinson's Disease (PD) in combination with Carbidopa
Parkinsonism post encephalitic
Used to treat Parkinsonism post encephalitic in combination with Carbidopa
Manganese Poisoning
Used to treat manganese intoxication in combination with Carbidopa
Carbon Monoxide Poisoning
Used to treat carbon monoxide intoxication in combination with Carbidopa

Effectiveness

How Inbrija Affects PatientsLevodopa is designed to pass through the blood-brain barrier, while dopamine is not. To ensure that as much levodopa as possible reaches the brain, a dopa decarboxylase inhibitor is added to the drug. This stops it from being converted to dopamine outside of the blood-brain barrier. Once inside the blood-brain barrier, it is then converted to dopamine by another enzyme.
How Inbrija works in the bodyLevodopa passes through the blood-brain barrier and is converted into dopamine. This dopamine acts as a replacement for the dopamine that the brain is missing, and stimulates dopamine receptors.

When to interrupt dosage

The recommended amount of Inbrija is contingent upon the diagnosed condition, for instance manganese intoxication, Parkinson's Disease and Restless Legs Syndrome (RLS). The dosage likewise fluctuates as per the technique of delivery outlined in the table beneath.
Condition
Dosage
Administration
Parkinson's Disease
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
Manganese Poisoning
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
Parkinson Disease
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
Restless Legs Syndrome
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
advanced Motor fluctuations
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
Carbon Monoxide Poisoning
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
Parkinson Disease
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
Parkinsonism post encephalitic
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)

Warnings

Inbrija Contraindications
Condition
Risk Level
Notes
Malignant Neoplasms
Do Not Combine
Pulse Frequency
Do Not Combine
cutaneous lesions
Do Not Combine
There are 20 known major drug interactions with Inbrija.
Common Inbrija Drug Interactions
Drug Name
Risk Level
Description
Azelastine
Major
Levodopa may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Ethanol
Major
Levodopa may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Macimorelin
Major
The therapeutic efficacy of Macimorelin can be decreased when used in combination with Levodopa.
Methylene blue
Major
Levodopa may increase the serotonergic activities of Methylene blue.
Mirtazapine
Major
Levodopa may increase the serotonergic activities of Mirtazapine.
Inbrija Toxicity & Overdose RiskThere is no known safety information regarding levodopa use during pregnancy. Rabbit studies have shown that taking levodopa and carbidopa can lead to smaller litters and birth defects. Levodopa may reduce the production of prolactin and interfere with breastfeeding. It is present in human breast milk and so nursing mothers should be warned of the potential effects before taking levodopa. There is also insufficient data about the use of levodopa in children under 18 years old. People over 65 years of age may be more likely to experience side effects when taking levodopa, but it should not automatically exclude them from treatment.

Inbrija Novel Uses: Which Conditions Have a Clinical Trial Featuring Inbrija?

48 active studies are currently underway to assess the potential of Inbrija to provide relief from Parkinson's Disease, Parkinsonism and carbon monoxide intoxication.
Condition
Clinical Trials
Trial Phases
Carbon Monoxide Poisoning
0 Actively Recruiting
Manganese Poisoning
0 Actively Recruiting
Parkinson Disease
0 Actively Recruiting
Restless Legs Syndrome
3 Actively Recruiting
Not Applicable
Parkinson's Disease
39 Actively Recruiting
Not Applicable, Phase 1, Phase 4, Phase 2, Phase 3, Early Phase 1
Parkinsonism post encephalitic
0 Actively Recruiting
advanced Motor fluctuations
0 Actively Recruiting
Parkinson Disease
0 Actively Recruiting

Inbrija Reviews: What are patients saying about Inbrija?

5Patient Review
1/15/2020
Inbrija for Parkinson's Disease
Super easy to set up, and it doesn't make me gag or cough excessively like some other treatments I've tried. Really helps me out when I need it!
4.3Patient Review
10/4/2019
Inbrija for Parkinson's Disease
Though it's tough to inhale, this medication works quickly and gets me through my off times. I take Rytary 4 x 4. Right now, I'm trying it out to see how much it will cost.
4.3Patient Review
2/1/2022
Inbrija for Parkinson's Disease
I've had PD for 22 years and Inbrija has been a real godsend. I'm careful to not overuse it, but it's still tempting because it works so well. That said, its effectiveness does seem to wane the more you use it.
3.7Patient Review
9/19/2019
Inbrija for Parkinson's Disease
You might cough a lot and have a histamine reaction the first time you use this, so be prepared. It's not pleasant, but it does work.
2.3Patient Review
9/25/2019
Inbrija for Parkinson's Disease
The idea behind this treatment is good, but the delivery method is very ineffective. It's hard to inhale the powder and I end up coughing for 15 minutes afterwards. Not worth it for me.
2.3Patient Review
10/10/2019
Inbrija for Parkinson's Disease
Inhaling this powder will cause an intense gag reflex or coughing. It's difficult to use as a result; I often accidentally coughed it back up after inhaling. However, the product did seem to work well after I took a double dose of the recommended amount.
2.3Patient Review
8/9/2019
Inbrija for Parkinson's Disease
This medication is effective in treating my off periods, but the process of taking it is really unpleasant. Inhaling the medicine feels like breathing in a dusty sandstorm.
1.7Patient Review
10/10/2019
Inbrija for Parkinson's Disease
Inhaling this powder is very difficult, as most of it just ends up coating the inside of my mouth. It also makes me cough and gag. I haven't noticed any difference in my tremor or gait after taking Inbrija.
1.3Patient Review
7/4/2021
Inbrija for Parkinson's Disease
I'm really disappointed in this treatment. After following all the set-up steps, I began coughing and choking when I inhaled. My throat is now irritated and I hope I don't get pneumonitis from this...
1Patient Review
7/4/2021
Inbrija for Parkinson's Disease
Terrible! I followed the instructions to a tee and still found myself choking and coughing. My throat is now irritated on top of it all. I really hope I don't get pneumonitis from this.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about inbrija

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What drug class is Inbrija?

"Inbrija is a drug that is used to treat Parkinson's disease. It belongs to a class of drugs called Antiparkinson Agents, Dopamine Precursors. It is not known if Inbrija is safe and effective in children."

Answered by AI

What happens if you swallow Inbrija?

"If you cough or feel like you're choking after using this medication, or if you experience any of the following side effects, call your doctor or pharmacist. These side effects include dizziness, lightheadedness, nausea, trouble sleeping, unusual dreams, a stuffy or runny nose, a sore throat, or a fever."

Answered by AI

How long does it take for Inbrija to work?

"The effects of INBRIJA tended to last for at least 3 hours.

INBRIJA has been shown to start working as early as 10 minutes in large clinical trials, with meaningful improvement in motor symptoms seen by 30 minutes. The effects of INBRIJA tended to last for at least 3 hours."

Answered by AI

What is Inbrija used for?

"Indication: INBRIJA is a prescription medicine used to treat OFF episodes in adults with Parkinson's who are taking regular carbidopa/levodopa medication. INBRIJA does not replace regular carbidopa/levodopa medication."

Answered by AI

Clinical Trials for Inbrija

Have you considered Inbrija clinical trials? We made a collection of clinical trials featuring Inbrija, we think they might fit your search criteria.Go to Trials
Image of Centre for Brain and Mind, Western University in London, Canada.

Cognitive Cueing + Video Intervention for Parkinson's Disease

40 - 99
All Sexes
London, Canada
The goal of this clinical trial is to learn if cognitive cueing (eg., prompting individuals to think about taking big-long steps while walking), either as a stand- alone intervention or combined with a personalized gait training video, can improve gait (walking), mobility, and balance confidence for individuals with Parkinson's Disease. The main questions it aims to answer are: 1. Does focusing on cognitive cues while walking improve gait, mobility, and balance confidence for individuals with Parkinson's Disease? 2. Does incorporating a personalized gait training video alongside cognitive cueing lead to amplified improvements in gait, mobility, and balance confidence for individuals with Parkinson's Disease? Researchers will compare how gait, mobility, balance confidence and quality of life change over time for participants when they practice walking with and without a cognitive cue alone, and when they practice with using a personalized gait training video. The researchers are also interested in how participation in this trial will affect quality of life and conscious attention to gait. Participants will * Complete walking trials on an instrumented mat that records data on their walking ability. These trials will be undertaken without a cognitive cue and while participants mentally rehearse a series of 3 cognitive cues (Take big long steps; Walk heel-toe; Stand up straight). * Be informed about which of the 3 cues best improved their walking and will receive a personalized gait training video for at home practice. * Complete online surveys that ask questions about their Parkinson's Disease, mobility, balance confidence quality of life and conscious attention to gait. * Visit the research facility 3 to 4 times during the study to have their gait (walking), mobility, balance confidence, quality of life and conscious attention to gait assessed and reassessed. * Practice both with and without their personalized video at home and keep a diary to record their practice sessions * Participate in a brief interview to discuss their experiences with the training and their perceptions of the effectiveness of cognitive cues and video-recorded feedback
Waitlist Available
Has No Placebo
Centre for Brain and Mind, Western University
Image of Sunnybrook Health Sciences Centre in Toronto, Canada.

Cannabis for Restless Legs Syndrome

18+
All Sexes
Toronto, Canada
Restless Legs Syndrome (RLS) is a disorder that causes painful and uncomfortable sensations in the legs, and its symptoms have a significant impact on sleep and quality of life. Cannabis has been used by some RLS patients as a treatment due to its painkilling and drowsiness effects, however there has never been a clinical research trial investigating cannabis in patients with RLS. A controlled trial is needed to establish how safe and feasible cannabis is as a treatment for RLS. The investigators plan to randomize 30 participants with moderate-to-severe RLS to receive either cannabis or placebo for 8 weeks. The investigators will measure patients sleep quality and quality of life at baseline and 8-week follow-up. The investigators will also monitor patients for any adverse reactions to the study drug.
Recruiting
Drug
Sunnybrook Health Sciences Centre (+1 Sites)
Have you considered Inbrija clinical trials? We made a collection of clinical trials featuring Inbrija, we think they might fit your search criteria.Go to Trials
Image of Austin Clinic PPD in Austin, United States.

LY3962681 for Parkinson's Disease

30 - 80
All Sexes
Austin, TX
The purpose of this study is to evaluate the safety, tolerability, and PK/PD of LY3962681 in healthy volunteers and patients with Parkinson's disease. The study will be comprised of two parts, the Single Ascending Dose (SAD) study and the Multiple Ascending Doses (MAD) study. During the SAD portion of the study, healthy volunteers will receive a single dose of LY3962681 or placebo (artificial cerebrospinal fluid (aCSF), no active drug) given into the spinal fluid. During the MAD portion of the study, patients with Parkinson's disease will receive two doses of either LY3962681 or placebo (aCSF) administered into the spinal fluid. * The treatment period in the SAD study will be 1 day. The treatment period in the MAD study will be 2 days, 12 to 24 weeks apart. * The follow-up period in the SAD study will be up to 52 weeks. The follow-up period in the MAD study will be up to 52 weeks post Dose 2.
Phase 1
Recruiting
Austin Clinic PPDTravis LewisPrevail Therapeutics
Image of Edward Hines Jr. VA Hospital, Hines, IL in Hines, United States.

Non-Invasive Vagal Nerve Stimulation for Parkinson's Disease

50 - 88
All Sexes
Hines, IL
More than 110,000 US Veterans living with Parkinson's disease (PD) currently receive PD-related care and services from the VA. Fall prevention is a priority for Veterans living PD. Gait disturbances are a major cause for functional dependence and the largest risk factor for falls, institutionalization, and death in PD. This SPiRE addresses the need to advance nonpharmacological rehabilitative health care of Veterans and maximizing functional outcomes by developing a non-invasive, neuromodulatory transcutaneous cervical Vagal Nerve Stimulation as an at-home intervention to improve gait and balance. This pilot clinical trial will assist with future efforts and priorities of the VA to prolong independent living and quality of life by minimizing gait and balance dysfunction experienced by Veterans living with PD.
Waitlist Available
Has No Placebo
Edward Hines Jr. VA Hospital, Hines, ILSandra L. Kletzel, PhD BA
Have you considered Inbrija clinical trials? We made a collection of clinical trials featuring Inbrija, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security